They went on to demonstrate a causal association between post-chemotherapy CSC enrichment with TGF-β signaling, which upon pharmacological intervention prevented in vivo tumor relapse in pre-clinical modes of TNBC (154). This evidence concerns the gene TGFB1 and neoplasm.